Jimin Kim is Group Leader of Analytical Development at Samsung Biologics, where she leads analytical method development, qualification, product characterization, and stability studies for biologics programs within the CDO organization. Prior to her current role, she led analytical development for adeno-associated virus (AAV) programs, supporting analytical strategy and method development for gene therapy products. Before joining Samsung Biologics, she worked at Daewoong Pharmaceutical Inc., where she was involved in identifying new therapeutic indications, efficacy evaluation, and analytical method development. She holds a Ph.D. in Biotechnology from Yonsei University.